首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1616085

非鴉片類疼痛治療市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Non-opioid Pain Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年09月02日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年全球非鴉片類疼痛治療市場價值為472億美元，預計2024年至2032年複合年成長率為7.3%。癮及其風險。隨著越來越多的人面臨關節炎、背痛和神經性問題等疾病，對有效疼痛管理藥物的需求激增。隨著人們越來越轉向更安全的疼痛管理方案，對鎮痛藥和非類固醇抗發炎藥等非鴉片類藥物的需求顯著增加，推動了市場擴張。這一趨勢主要是由於患者尋求鴉片類藥物的替代品以有效緩解疼痛且沒有相關風險而推動的。

整個非鴉片類疼痛治療產業根據藥物類別、藥物類型、適應症、給藥途徑、配銷通路和地區進行分類。非鴉片類疼痛治療市場依藥物類別細分，包括局部麻醉藥、非類固醇抗發炎藥、抗憂鬱藥、止痛藥、抗痙攣藥等。 NSAIDs 細分市場將在 2023 年引領市場，預計在整個預測期內將保持其主導地位，複合年成長率為 7.1%。非類固醇抗發炎藥在治療肌肉骨骼、發炎和急性疼痛方面的廣泛使用和有效性有助於其市場領先地位。

可透過非處方藥 (OTC) 和處方購買，拓寬了其可及性。非類固醇抗發炎藥物能夠減輕疼痛和炎症，且沒有鴉片類藥物的風險，這使其成為醫療保健提供者和患者的首選。到 2023 年，口腔細分市場將佔據 42.9% 的市場佔有率，並預計在整個分析期內保持領先地位。口服途徑的主導地位源自於其便利性、有效性和廣泛的可用性。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	472 億美元
預測值	884 億美元
複合年成長率	7.3%

許多患者，即使是那些患有急性或嚴重疼痛的患者，也更喜歡口服藥物，因為它們可以快速緩解疼痛并且無需處方。對鴉片類藥物風險認知的提高進一步促使消費者轉向更安全的口服替代品。因此，口腔領域在疼痛管理中的既定作用以及對非鴉片類藥物解決方案不斷成長的需求強化了其主導地位。 2023年，美國以192億美元的估值引領北美非鴉片類疼痛治療市場，預計未來幾年將顯著成長。對替代性疼痛管理解決方案的需求明顯，這主要是由於持續的鴉片類藥物危機和慢性疼痛的廣泛流行所推動的。美國也因其在非鴉片類藥物治療方面的創新而脫穎而出，這得益於其先進的醫療基礎設施、強勁的研發投資以及頂級製藥公司的存在。

產業生態系統分析
產業影響力
- 成長動力
  - 老年人口增加和對疼痛管理的關注
  - 提高對鴉片類藥物使用相關風險的認知
  - 擴大研究經費和活動
  - 藥物輸送系統不斷進步
- 產業陷阱與挑戰
  - 副作用和安全問題
  - 替代療法和非藥物方法的可用性
成長潛力分析
管道分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
非類固醇類抗發炎藥 (NSAID)
局部麻醉劑
抗憂鬱藥
抗驚厥藥
止痛藥
其他藥物類別

第 6 章：市場估計與預測：按藥物類型，2021 - 2032 年

主要趨勢
場外交易 (OTC)
處方

第 7 章：市場估計與預測：按指標分類，2021 - 2032 年

主要趨勢
神經性疼痛
術後疼痛
慢性背痛
癌症痛
偏頭痛
關節炎疼痛
肌肉扭傷/拉傷
其他適應症

第 8 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
專題
可注射
其他給藥途徑

第 9 章：市場估計與預測：按配銷通路，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 10 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Amgen Inc.
Almatica Pharma LLC
Eli Lilly and Company
Fresenius Kabi AG
GlaxoSmithKline plc
Haleon group
Heron Therapeutics
Hyloris Pharmaceuticals
Johnson & Johnson Consumer Inc.
Neumentum Inc.
Novartis AG
Par Pharmaceutical, Inc.
Pfizer Inc.
Sanofi
Scilex Holding Company
Sun Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals
WEX Pharmaceuticals Inc.

簡介目錄

Product Code: 11178

The Global Non-Opioid Pain Treatment Market was valued at USD 47.2 billion in 2023 and is projected to grow at a CAGR of 7.3% from 2024 to 2032. This growth can be attributed to the rising incidence of chronic pain conditions and heightened concerns over opioid addiction and its risks. With a growing number of individuals facing disorders like arthritis, back pain, and neuropathic issues, the demand for effective pain management drugs has surged. With a growing shift towards safer pain management options, the demand for non-opioid treatments like analgesics and non-steroidal anti-inflammatory drugs has seen a significant rise, driving market expansion. This trend is largely fueled by patients seeking alternatives to opioids for effective pain relief without the associated risks.

The overall non-opioid pain treatment industry is classified based on drug class, medication type, indication, route of administration, distribution channel, and region. The non-opioid pain treatment market is segmented by drug class, including local anesthetics, NSAIDs, antidepressants, analgesics, anticonvulsants, and others. The NSAIDs segment led the market in 2023 and is projected to maintain its dominance with a CAGR of 7.1% throughout the forecast period. NSAIDs' widespread use and effectiveness in treating musculoskeletal, inflammatory, and acute pain contribute to their market leadership.

Being available both over-the-counter (OTC) and via prescription broadens their accessibility. NSAIDs' capability to alleviate pain and inflammation without the risks tied to opioids has made them a preferred choice for healthcare providers and patients alike. The oral segment, commanding a 42.9% market share in 2023, is poised to retain its lead throughout the analysis period. The oral route's dominance stems from its convenience, effectiveness, and broad availability.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$47.2 Billion
Forecast Value	$88.4 Billion
CAGR	7.3%

Many patients, even those with acute or severe pain, prefer oral medications for their rapid relief and non-prescription nature. Heightened awareness of opioid risks has further nudged consumers towards safer oral alternatives. Consequently, the oral segment's established role in pain management and the rising demand for non-opioid solutions reinforce its dominance. In 2023, the U.S. led the North American non-opioid pain treatment market with a valuation of USD 19.2 billion, and significant growth is anticipated in the coming years.Several pivotal factors underpin the U.S.'s dominance in the North American market. There's a pronounced demand for alternative pain management solutions, largely driven by the ongoing opioid crisis and the widespread prevalence of chronic pain conditions. The U.S. also stands out for its innovation in non-opioid treatments, thanks to its advanced healthcare infrastructure, robust R&D investments, and the presence of top-tier pharmaceutical companies.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising geriatric population and concern for pain management
  - 3.2.1.2 Increasing awareness of the risks associated with opioid use
  - 3.2.1.3 Expanding research funding and activities
  - 3.2.1.4 Growing advancements in the drug delivery system
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects and safety concerns
  - 3.2.2.2 Availability of alternative therapies and non-pharmacological approaches
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.3 Local anesthetics
5.4 Antidepressants
5.5 Anticonvulsants
5.6 Analgesics
5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Over-the-counter (OTC)
6.3 Prescription

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Neuropathic pain
7.3 Post-operative pain
7.4 Chronic back pain
7.5 Cancer pain
7.6 Migraine
7.7 Arthritic pain
7.8 Muscle sprain/strain
7.9 Other indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Topical
8.4 Injectable
8.5 Other routes of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa